Nectar Lifesciences Limited

Closure of Trading Window for Buyback of Shares

Trading window closed from November 27, 2025, until 48 hours after the board meeting on December 03, 2025, for the buyback of shares. Designated persons are prohibited from trading during this period.

NECLIFE Announces Financial Results Publication for Quarter Ended September 30, 2025

Nectar Lifesciences Limited announces the publication of its financial results for the quarter and half-year ended September 30, 2025, in Business Standard and Desh Sewak newspapers.

NECLIFE Announces Change in Registered and Corporate Office

Nectar Lifesciences Limited changes its registered and corporate office addresses, effective November 14, 2025.

Nectar Lifesciences Board Approves Q2 FY26 Results, Reports Significant Losses Amidst Business Divestment

Nectar Lifesciences' board approved Q2 FY26 standalone and consolidated results, reporting significant losses primarily from discontinued operations. The company completed the ₹127,398.55 lacs sale of its Pharma and Menthol businesses.

Nectar Lifesciences Concludes Slump Sale and Asset Sale

Nectar Lifesciences concludes slump sale and asset sale. The final consideration under BTA is ₹1253.99 crore and APA consideration remained at ₹20.00 crore.

NECLIFE: KMP and Senior Management Transferred Pursuant to Slump Sale

Nectar Lifesciences transfers key managerial and senior management personnel to Ceph Lifesciences following a business transfer agreement, effective November 10, 2025. Dr. Surulichamy Senthilkumar remains as Non-Executive Director.

Nectar Lifesciences completes slump sale of API and formulations business and asset sale

Nectar Lifesciences completed the slump sale of its API and formulations business and an asset sale to Ceph Lifesciences Private Limited, effective November 10, 2025, as per agreements dated July 7, 2025.

Nectar Lifesciences: Vice President (Exports) Ashok Kumar resigns effective Nov 09, 2025

Nectar Lifesciences Limited announced the resignation of Mr. Ashok Kumar, Vice President (Exports), effective November 09, 2025, due to personal reasons.

Nectar Lifesciences announces Internal Auditor Mr. Aman Singla's resignation

Nectar Lifesciences announced the resignation of its internal auditor, Mr. Aman Singla, effective November 03, 2025, due to personal reasons and other commitments.

Disclosure regarding release of pledge from promoters holding

SBICAP Trustee Company Limited released the pledge from the promoters' holding in Nectar Lifesciences Limited on repayment of loan. Pledge of 9,94,68,000 Equity Shares (44.35%) released on 30 October 2025.

Disclosure under Insider Trading Regulations - Release of Pledged Shares

Nectar Lifesciences' promoters, Mr. Sanjiv Goyal and Sanjiv HUF, disclosed the release of pledged shares under insider trading regulations; executed by SBICAP Trustee Company Limited on October 29, 2025.

EXIM Bank withdraws nomination of Ms. Meena Verma as Nominee Director from Nectar Lifesciences Board

EXIM Bank has withdrawn the nomination of Ms. Meena Verma as Nominee Director from Nectar Lifesciences Limited's Board, effective October 27, 2025.

Nectar Lifesciences Fully Repays Secured Debt of ₹1,338.35 Crore

Nectar Lifesciences Limited has fully repaid its secured debt of ₹1,338.35 crore to consortium lenders, and the consortium charge on all assets has been completely satisfied, registered on 22 Oct 2025.

Nectar Lifesciences extends Slump Sale completion date to Ceph Lifesciences until November 19, 2025

Nectar Lifesciences and Ceph Lifesciences mutually agreed to extend the Slump Sale completion date for the API and formulations business to on or before November 19, 2025.

Nectar Lifesciences Ltd: Outcome of 30th AGM held on September 29, 2025

Nectar Lifesciences held its 30th AGM on September 29, 2025, via video conferencing, where all five resolutions were passed with the required majority. Sanjiv Goyal was re-appointed as director.

Nectar Lifesciences receives Regulation 74(5) compliance certificate for Q2 FY26

Nectar Lifesciences confirmed compliance with SEBI Regulation 74(5) for the quarter ended September 30, 2025, regarding securities dematerialization processes through a certificate from its RTA.

Nectar Lifesciences Ltd concludes 30th Annual General Meeting

Nectar Lifesciences extends Slump Sale completion date to October 20, 2025

Nectar Lifesciences undergoes search operations by Directorate of Revenue Intelligence

Clarification on Financial Results for NECLIFE PT, UNIPESSOAL LDA

Nectar Lifesciences announces 30th AGM on September 29, 2025 via VC/OAVM

Nectar Lifesciences to appeal rejection of ₹3.50 crore refund claim

Nectar Lifesciences to hold 30th AGM on September 29, 2025; key resolutions on financials, director re-appointment, and auditor remuneration

NECLIFE Launches 'Saksham Niveshak' Campaign for Shareholder Outreach

NECLIFE: Newspaper Publication of Financial Results for Quarter Ended June 30, 2025

Nectar Lifesciences Unit VI receives Ukraine GMP certification

NECLIFE EGM approves director appointments, business transfer to Ceph Lifesciences

Corrigendum to EGM Notice Regarding Special Dividends and/or Buyback

Nectar Lifesciences Board Addresses and Pays Fines for Regulatory Non-Compliance

NECLIFE: Corrigendum to EGM Notice - Special Dividends and/or Buyback